Entehep 1mg

Entehep 1mg tablets are used as anti-viral medicine, the safety and effectiveness of the Entehep 1mg has been established against chronic hepatitis B viral infection. Entehep 1mg contains an active compound known as Entecavir. Entehep 1mg is a classified as prototype for cyclopentane class of nucleoside or nucleotide long lasting hepatitis B anti-viral drug. Entecavir is coordinate with development of minimal resistance in long term therapy of nucleoside naïve patients.






The critical points take into consideration, while starting the therapy with Entehep 1mg tablets; Indication of Entehep 1mg is established by clinical trial data in nucleoside inhibitor-therapy naïve and lamivudine resistant patients with HBeAg positive and HBeAg negative HBV infection and compensated liver cirrhosis & decompensated cirrhosis. Entehep 1mg is used in pediatric patients with 2 years of age or older, with treatment naïve, lamivudine resistant with HBeAg positive HBV infection & compensated liver cirrhosis.

Main indication:
Entehep 1mg tablets are used to treat chronic hepatitis B viral infection commonly in adolescent patients with the sign of viral multiplication and other information of lasting elevation of serum aminotransferase or active disease.


Entehep 1mg enclose as Entecavir as an active component, a synthetic analogue of 2-deoxyguanosine has anti-viral activity against hepatitis B virus.

Entecavir is triggers in-vivo into 5-triphosphate metabolite which is an active form of Entecavir.

Consecutively, the active metabolite triphosphate form collides with natural substrate deoxyguanosine triphosphate dGTP for insertion into viral DNA. Thus, the inclusion of the activated triphosphate metabolite of Entecavir causes prohibition of reverse transcriptase enzyme.

RT is responsible for viral production and transcription, thus inhibition results as cell lysis.

ADME Properties

Entehep 1mg tablet, after an oral administration it may undergo ADME properties. The peak plasma concentration time of Entehep 1mg is occurs within 0.5 & 1.5 hours. The steady state of Entehep 1mg is reaches after 6 to 10 days of single dose administration. Entehep 1mg Cmax value is 4.2ng/ml and trough plasma concentration are 0.3ng/ml

Oral administration of Entehep 1mg with high fat meal causes decreasing the absorption, depletes Cmax of 44 to 46%, decreases AUC of 18 to 20%.

The volume of distribution is exuberance of total body water; Entecavir is largely distributed into tissues. The binding of Entecavir with serum proteins occurs relatively 13%.

Entecavir should not be considering as cytochrome P450 enzymes substrate, inhibitor or inducers, which is adequately phosphorylated into an active triphosphate form.

Entehep 1mg tablets after metabolism get eliminated via kidneys, in an unchanged form with the range 62% to 73%. The plasma concentration of Entehep 1mg depletes in bi-exponential manner with the mean terminal half life period of relatively 128 to 148 hours and the phosphorylated metabolite half life is 15 hours.


Brand Entehep
Ingredients Entecavir
Strength 1mg
Manufactured Zydus


The dosage recommendation of Entehep tablets are given below as follows;

In compensated liver disease

The usual dosage of Entehep tablet for this condition in adults is 0.5mg should be recommended as a single dose. History of hepatitis B viremia in patients: At the time of getting lamivudine or well-known lamivudine or telbivudine opposed substitutions like rtM204I/V with or without rtL180M, rtL80I/v, or rtV173L, in this situation the recommended dosage of Entehep 1mg is 1mg should be administered as a single dose.

In decompensated cirrhosis

In chronic hepatitis B viral infected patients, the prescribed dosage of Entehep is 1mg should be given orally as a single dose.

In pediatric patients

For therapy naïve patients

The recommended dosage of Entehep tablet is 0.5mg should be given as a single dose.

For lamivudine resistance

The prescribed dosage is 1mg of Entehep should be taken as a single dose.

For renal impairment patients

CrCl 50ml/min or greater: The recommended dosage is 0.5mg of Entehep given as a single dose CrCl 30 to less than 50ml/min: The recommended dosage is 0.5mg of Entehep given for every 48 hours CrCl 10ml/min to less than 30ml/min: The prescribed dosage is 0.5mg of Entehep should be given for every 72 hours. CrCl less than 10ml/min & hemodialysis, CAPD: The suggested dosage is 0.5mg of Entehep given for every 7 days.

In lamivudine resistant or decompensated cirrhosis

CrCl 50ml/min or greater: The recommended dosage is 1mg of Entehep 1mg given as a single dose CrCl 30 to less than 50ml/min: The recommended dosage is 0.5mg of Entehep given as a single dose or 1mg for every 48 hours. CrCl 10ml/min to less than 30ml/min: The prescribed dosage is 1mg of Entehep should be given for every 72 hours. CrCl less than 10ml/min & hemodialysis, CAPD: The suggested dosage is 1mg of Entehep given for every 7 days.

How to administer Entehep 1mg tablets

Enteheptablet should be given for chronic hepatitis B viral infected patients, taken in an empty stomach i.e., partially 2 hours after a meal and 2 hours earlier the next meal.

The most common adverse reaction occurs during or after the treatment

• Severe aggravation of hepatitis B infection
• Lactic acidosis
• Hepatomegaly with steatosis

The common side effects like

Dyspepsia, Alopecia, Rash, Elevation of transaminase, Headache, Fatigue, Anaphylactic reactions, Dizziness, Diarrhea, Nausea, Vomiting, Somnolence, Insomnia, Hepatic failure, Gastrointestinal hemorrhage, Hepatocellular carcinoma


Some precautions should be taken while starting therapy with Entehep;

In severe acute aggravation of hepatitis B

This adverse may occur after discontinuation of anti-hepatitis B therapy. In this condition patient should be monitored frequently with liver functions and other laboratory follow ups. Continue the anti-hepatitis B therapy, if required.

In HBV/HIV-1 co infected patients

Entecavir has not assessed in HIV/HBV co infected patients who are not concurrently taking effective anti-retroviral therapy. Entehep 1mg tablet used for HBV infection in patients who are infected with HIV, produce resistant to HIV nucleoside reverse transcriptase inhibitors, not exist to treat. Entehep 1mg should not be suggested to HBV/HIV co infected patients, also not receiving HAART. To overcome this type of condition, patient should be examining with HIV antibody testing before the therapy.

In lactic acidosis & hepatomegaly with steatosis

This condition may occur due to the combination of nucleoside analog with anti-retroviral agents, this may happen mostly in women. The major fatal cases of this condition are obesity and extended nucleoside exposure. Lactic acidosis frequently occurs in decompensated liver cirrhosis patients, the only way to reduce this adverse is discontinuing the treatment with Entehep.


  • Entehep 1mg is not a CYP 450 enzyme substrate, inhibitor or inducers.

  • Since Entehep 1mg is majorly eliminated through kidneys, co administration of Entehep 1mg tablets with drugs which reduce the renal functions causes increasing the serum concentration of Entecavir and other combined drugs leads to adverse effects of Entehep.

  • Drug interaction may occur during combination of Entehep 1mg with the drugs which metabolized, inhibit or induce by CYP450 enzyme may have chance to alter pharmacokinetic properties of Entecavir.

  • Co administration of Entehep 1mg with lamivudine, Adefovir or tenofovir disoproxil fumarate not expels any drug interaction.


No contraindication is acquired in the therapy using with Entehep 1mg tablets. Any hypersensitivity reaction occurs, if patients who are contraindicated to the ingredients present in Entehep 1mg tablets.

Entehep 1mg usage in


The pregnancy category of Entehep 1mg tablets is C Entehep 1mg tablets should not be used in pregnancy condition. Entehep 1mg used in pregnancy for necessary condition, if risk and benefits are clearly known.

Renal impairment

Depending upon creatinine clearance, the dosage of Entecavir is suggested for patients who are having renal damage. They may follow the dosage adjustments. The safety and effectiveness of Entecavir in hepatic impaired patients has not been evaluated.


In pediatric patient age of less than 2 years, the potency of Entehep 1mg has not been assured. Care should be taken while using in pediatric patients.


In animal clinical studies reveals that Entecavir is excreted in human milk, but human data is not applicable. Breast feeding should be avoided, because most of the drugs are eliminated in human milk. To avoid problems related to Entecavir, it should be taken into consideration.

Hepatic impairment

If Entehep 1mg is necessary to take in hepatic impairment patients, who are already receiving Immuno suppressant like cyclosporine, Tacrolimus or sirolimus causes affecting the renal function. Patient must examine periodically before or after the therapy using with Entehep 1mg


In geriatric patient who have renal impairment, while taking Entehep 1mg caution should be taken because it is renal eliminated medicine. In elder patients’ renal functions are mostly decreased.


Entehep 1mg tablets should be stores at below 30°C Keep away from light, moisture and heat. The shelf life of Entehep tablets is 2 years from the date of manufacture.

If over dosage of Entecavir occurs, confirmation of toxicity should be taken and provide supportive measures. Following 1mg of Entecavir, nearly 13% of Entecavir dose should be eliminated by hemodialysis method.

Entehep 1mg tablets are anti-hepaciviral drug, used only by getting advice from medical practitioner.

If patient fail to take the dose of Entehep, must consult with physician and follow the instructions given by them. On the other hand, skip the missed dose and follow the regular dosing schedule.

Quick Contact

Prescription upload


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.